Weiss Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Weiss Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-274,142	Closed	-$50.4M	–	729
2021 Q2	$50.4M	Buy	274,142 +76,186	+38%	+$13.1M	1.25%	11
2021 Q1	$30.3M	Buy	+197,956	New	+$30.6M	0.82%	27
2018 Q4	–	Sell	-4,150	Closed	-$577K	–	505
2018 Q3	$577K	Hold	4,150	–	–	0.04%	116
2018 Q2	$515K	Hold	4,150	–	–	0.05%	114
2018 Q1	$463K	Hold	4,150	–	–	0.04%	122
2017 Q4	$496K	Buy	4,150 +2,612	+170%	+$318K	0.04%	123
2017 Q3	$216K	Buy	+1,538	New	+$209K	0.02%	89

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Weiss Asset Management's ALXN Position: Q3 2021 in Review

Weiss Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 274,142 shares — an estimated $50.4M sold.

Weiss Asset Management first reported a position in ALXN in Q3 2017 and held it in 7 quarters. The position peaked at $50.4M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Weiss Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Weiss Asset Management sold 274,142 Alexion Pharmaceuticals shares in Q3 2021, an estimated $50.4M.
Weiss Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 7 quarters.
Weiss Asset Management's Alexion Pharmaceuticals position peaked at $50.4M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Weiss Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.